Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

734 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.
Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Yoshino T, et al. Among authors: bando h. Ann Oncol. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. Epub 2021 Aug 16. Ann Oncol. 2021. PMID: 34411693 Free article.
Metyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing's syndrome.
Tsujimoto Y, Yamamoto N, Bando H, Yamamoto M, Ohmachi Y, Motomura Y, Oi-Yo Y, Sasaki Y, Suzuki M, Urai S, Takahashi M, Iguchi G, Ogawa W, Fukuoka H. Tsujimoto Y, et al. Among authors: bando h. Front Endocrinol (Lausanne). 2024 Dec 23;15:1511155. doi: 10.3389/fendo.2024.1511155. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39764253 Free PMC article.
Mathematical modeling predicts optimal immune checkpoint inhibitor and radiotherapy combinations and timing of administration.
Sakai SA, Saeki K, Chi S, Hamaya Y, Du J, Nakamura M, Hojo H, Kojima T, Nakamura Y, Bando H, Kojima M, Suzuki A, Suzuki Y, Akimoto T, Tsuchihara K, Haeno H, Yamashita R, Kageyama SI. Sakai SA, et al. Among authors: bando h. Cancer Immunol Res. 2024 Dec 12. doi: 10.1158/2326-6066.CIR-24-0610. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39666379
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Andre T, et al. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. N Engl J Med. 2024. PMID: 39602630 Clinical Trial.
734 results